Factors Affecting Treatment Outcome of Metastatic Breast Cancer: Single Institution Study

Sara  shamsaldin; Reem Mamdouh Abdelmalek; Noha Yehia   Ibrahim; Ahmed Abdelhafeez   Mohamed

doi:10.3889/oamjms.2023.11288

Authors

Sara shamsaldin Department of Clinical Oncology (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo, University, Cairo, Egypt https://orcid.org/0000-0001-5691-8118
Reem Mamdouh Abdelmalek Department of Clinical Oncology (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo, University, Cairo, Egypt
Noha Yehia Ibrahim Department of Clinical Oncology (NEMROCK)
Ahmed Abdelhafeez Mohamed Department of Clinical Oncology (NEMROCK), Kasr Al-Ainy School of Medicine, Cairo, University, Cairo, Egypt https://orcid.org/0000-0001-8200-5291

DOI:

https://doi.org/10.3889/oamjms.2023.11288

Keywords:

Metastatic breast cancer, Progression free survival, Treatment outcome, Decision making

Abstract

BACKGROUND: Metastatic breast cancer (MBC) is an incurable disease.

AIM: The goal of therapy is to prolong survival and amelioration of quality of life. However, the benefit of later systemic treatment lines is not clear.

METHODS: This was a retrospective study of 345 MBC patient., assessment of progression free survival (PFS) survival with first line of treatment and second, third, fourth, fifth, and sixth lines of therapy, and analysis of different prognostic factors.

RESULTS: The median overall survival (OS) was 31.7 month. The median PFS was 8.1 versus 3 month for first line of treatment and beyond. Where median PFS1, PFS 2, PFS 3, PFS 4, PFS 5, and PFS 6 were 8.1, 5.8, 3.8, 4.8, 3.4, and 2.6, respectively. PFS of first line was significantly prolonged in hormone positive luminal subtype, bone only metastasis, age above 35, ECOG I-II, and oligometastatic (p = 0.041, 0.038, 0.023, 0.034, 0.0001, and 0.001, respectively). Post-progression survival was 23.4 months and it was significantly prolonged in hormone positive luminal subtype, bone only metastasis, age above 35, ECOG I-II and PFS more than 6 months with first line.

CONCLUSION: PFS is reduced with using more treatment lines in MBC. Patients with luminal subtype, bone only metastasis, age above 35, ECOG I-II, and PFS more than 6 months with first line may have the best benefit from later lines.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660 PMid33538338 DOI: https://doi.org/10.3322/caac.21660

Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: Results of the national population- based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. https://doi.org/10.1155/2014/437971 PMid25328522 DOI: https://doi.org/10.1155/2014/437971

Kovic B, Jin X, Kennedy SA, Hylands M, Pedziwiatr M, Kuriyama A, et al. Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: A systematic review and quantitative analysis. JAMA Intern Med. 2018;178(12):1586-96. https://doi.org/10.1001/jamainternmed.2018.4710 PMid30285081 DOI: https://doi.org/10.1001/jamainternmed.2018.4710

Riggio I, Varley KE, WelmAL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer. 2021;124(1):13-26. https://doi.org/10.1038/s41416-020-01161-4 PMid33239679 DOI: https://doi.org/10.1038/s41416-020-01161-4

Kiely BE, Soon YY, Tattersall MH, Stockler MR. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: A systematic review of recent randomized trials. J Clin Oncol. 2011;29(4):456-63. https://doi.org/10.1200/JCO.2010.30.2174 PMid21189397 DOI: https://doi.org/10.1200/JCO.2010.30.2174

Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, et al. Measures of outcome in metastatic breast cancer: Insights from a real-world scenario. Oncologist. 2014;19(6):608-15. https://doi.org/10.1634/theoncologist.2014-0002 PMid24794159 DOI: https://doi.org/10.1634/theoncologist.2014-0002

Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol. 2010;28(1):92-8. https://doi.org/10.1200/JCO.2008.19.9844 PMid19933921 DOI: https://doi.org/10.1200/JCO.2008.19.9844

Bonotto M, Gerratana L, Iacono D, Minisini AM, Rihawi K, Fasola G, et al. Treatment of metastatic breast cancer in a real-world scenario: Is progression-free survival with first line predictive of benefit from second and later lines? Oncologist. 2015;20(7):719-24. https://doi.org/10.1634/theoncologist.2015-0002 PMid26018662 DOI: https://doi.org/10.1634/theoncologist.2015-0002

Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM, et al. Survival of patients with metastatic breast carcinoma: Importance of prognostic markers of the primary tumor. Cancer. 2003;97(3):545-53. https://doi.org/10.1002/cncr.11083 PMid12548595 DOI: https://doi.org/10.1002/cncr.11083

Regierer AC, Wolters R, Ufen MP, Weigel A, Novopashenny I, Köhne CH, et al. An internally and externally validated prognostic score for metastatic breast cancer: Analysis of 2269 patients. Ann Oncol. 2014;25(3):633-8. https://doi.org/10.1093/annonc/mdt539 PMid24368402 DOI: https://doi.org/10.1093/annonc/mdt539

Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol. 2008;19(12):2012-9. https://doi.org/10.1093/annonc/mdn424 PMid18641006 DOI: https://doi.org/10.1093/annonc/mdn424

Shen T, Gao C, Zhang K, Siegal GP, Wei S. Prognostic outcomes in advanced breast cancer: The metastasis-free interval is important. Hum Pathol. 2017;70:70-6. https://doi.org/10.1016/j.humpath.2017.10.002 PMid29031733 DOI: https://doi.org/10.1016/j.humpath.2017.10.002

Stuart-Harris R, Shadbolt B, Palmqvist C, Chaudri Ross HA. The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors. Breast. 2009;18(6):351-5. https://doi.org/10.1016/j.breast.2009.09.002 PMid19836952 DOI: https://doi.org/10.1016/j.breast.2009.09.002

Clark GM, Sledge GW Jr., Osborne CK, McGuire WL. Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987;5(1):55-61. https://doi.org/10.1200/JCO.1987.5.1.55 PMid3806159 DOI: https://doi.org/10.1200/JCO.1987.5.1.55

Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, et al. Prognosis of metastatic breast cancer: Are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer. 2015;112(9):1445-51. https://doi.org/10.1038/bjc.2015.127 PMid25880008 DOI: https://doi.org/10.1038/bjc.2015.127

Park IH, Lee KS, Ro J. Effects of second and subsequent lines of chemotherapy for metastatic breast cancer. Clin Breast Cancer.

;15(1):e55-62. https://doi.org/10.1016/j.clbc.2014.09.001 PMid25445418 DOI: https://doi.org/10.1016/j.clbc.2014.09.001

Cabel L, Carton M, Pistilli B, Dalenc F, Vanlemnens L, Levy C, et al. Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program. Breast. 2021;56:18-25. https://doi.org/10.1016/j.breast.2021.01.006 PMid33561617 DOI: https://doi.org/10.1016/j.breast.2021.01.006

Matikas A, Kotsakis A, Perraki M, Hatzidaki D, Kalbakis K, Kontopodis E, et al. Objective response to first-line treatment as a predictor of overall survival in metastatic breast cancer: A retrospective analysis from two centers over a 25-year period. Breast Care (Basel). 2022;17(3):264-71. https://doi.org/10.1159/000519729 PMid35949417 DOI: https://doi.org/10.1159/000519729